Several groups have declared July 2017 as Dry Eye Awareness Month.
TFOS DEWS II™ highlights will be presented at a July 12 Congressional Briefing entitled Dry Eye: An Updated Definition, A Greater Impact on Vision Health—co-hosted by TFOS and the Alliance for Eye and Vision Research (AEVR)—to be held from 12 Noon – 1:15 pm in Rayburn 2168 (Gold Room). The Briefing will be bookended by a “Test Your Tears” Dry Eye Screening and Dry Eye Researcher Poster Presentation from 11:30 am – 2 pm. The vision community is making Congressional education about dry eye a priority since it impacts healthcare policy, as it is one of the most frequent causes of patient visits to eye care providers, and since federal research funding from the National Institutes of Health (NIH), including its National Eye Institute (NEI), is being used to study dry eye causes and develop treatments.
Also, stay tuned for the TFOS DEWS II report, due 1 July 2017 in The Ocular Surface.
Dr. Novack attended the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Baltimore, MD. This was his approximately 33rd ARVO meeting. He presented in the Special Interest Group on the TFOS Dry Eye Workshop II. As well he had two side-by-side posters in a glaucoma poster session- one on an investigational drug, and the other on a recently cleared minimally-invasive glaucoma stent (MIGS). He was also an author on a oral presentation of an investigational drug to treat elevated intraocular pressure.
Dr. Novack in front of his two, side-by-side, posters on glaucoma therapies
TFOS DEWS II Chairs (Dr. Novack is 5th from left)
Dr. Novack gave a talk on the preclinical needs for development of ophthalmic products at the Spring meeting of the Boston Area Pharmacology Toxicology Group (BAPTG). The meeting was hosted by Biogen at their facility in Cambridge, MA.
Dr. Novack, a 30+ year member of the American Society of Clinical Pharmacology and Therapeutics, attended the annual meeting in Washington DC in March 2017. He participated in several trainee events, including a trainee luncheon (pictured below) and a “speed mentoring” event. He was a co-founder of the latter for this society.
Dr. Novack will be speaking at the Spring 2017 meeting of the Boston Area Pharmacology / Toxicology Group meeting on 7 April 2017. His topic is “Ophthalmic Product Development – from Preclinical to Efficacy Outcomes”. For those interested, here is the Eventbrite link for registration.
Dr. Novack attended the American Glaucoma Society meeting in Coronado (San Diego) 2-5 March 2017. He was an author on a paper on the aqueous humor dynamics of netarsudil, an topical ocular hypotensive drug currently in clinical trials for the treatment of glaucoma.